Skip to main content

Andreas Lundqvist's Group

Tumor immunology

Our research focuses to develop novel immunotherapy regimens for patients with cancer.

The immune system plays an important role to prevent local growth and dissemination of cancer. Therapies based on activating the immune system, in particular T and NK cells, result in beneficial responses in patients with cancer. However, the majority of patients fail to respond to immunotherapy. In order to harness the full potential of the immune system T and NK cells need to colonize tumors as well as to display optimal tumor killing potential. In several projects, we investigate the ability of T and NK cells to migrate towards tumors, to persist within the tumor microenvironment, and to maintain the ability to and recognize and kill tumor cells. We study how T and NK cells interact with cells within the tumor microenvironment and exploit cellular and molecular mechanisms of tumor-induced immunosuppression in order to develop improved immunotherapy regimens in patients with cancer. In these studies, we use different tumor models including renal cell carcinoma, thyroid cancer, neuroblastoma, melanoma, breast cancer, and lung cancer.

Group members

Andreas Lundqvist, Group leader
Kristina Witt, PhD student
Maria Wolodarski, PhD student
Ziqing Chen, PhD student
Shi Yong Neo, PhD student
Lisa Liu, Post-doc
Ying Yang, associated


Erik Wennerberg, Weill Cornell Medicine, New York

Dhifaf Sarhan, University of Minnesota and Karolinska Institutet

Veronika Kremer, Karolinska Institutet, Department of Medicine, Huddinge

Selected publications











List of all publications.


  • Swedish Research Council
  • Swedish Cancer Society
  • European Research Council
  • Karolinska Institutet
  • Jeanssons Stiftelse
  • Åke Wiberg Foundation
  • Magnus Bergvall Foundation
  • Fredrik och Ingrid Thurings Foundation
  • Clas Groschinskys Foundation
  • Swedish Society of Medicine
  • Wenner-Gren Foundation
  • The American Thyroid Association
  • Vinnova